54 results about "ATPase" patented technology

The invention provides an anti-human H < + > / K < + > ATPase beta protein monoclonal antibody as well as a hybridoma cell strain and application thereof, and belongs to the technical field of immune globulin. The invention provides an anti-human H < + > / K < + > ATPase beta protein monoclonal antibody and also provides a hybridoma cell strain OTI10F11, the hybridoma cell strain OTI10F11 is preserved in the China General Microbiological Culture Collection Center on April 26, 2025, and the preservation number of the hybridoma cell strain OTI10F11 is No.46356. The invention further provides an anti-human H < + > / K < + > ATPase beta protein monoclonal antibody. The hybridoma cell strain OTI10F11 provided by the invention can stably secrete an anti-human H < + > / K < + > ATPase beta protein monoclonal antibody, and can be specifically combined with H < + > / K < + > ATPase beta protein, so that the specificity, accuracy and reliability of immunodetection are remarkably improved, and the hybridoma cell strain OTI10F11 can be suitable for marking H < + > / K < + > ATPase beta protein in tissue cells.

The present disclosure features methods, e.g., dosing regimens, of treating cancer with SMARCA4 / SMARCA2 ATPase inhibitors.

The microalgae phenol degradation and carbon fixation technology aims to provide a method for improving key enzymes to promote euglena to degrade phenol and enhance carbon fixation. The method comprises the following steps: adjusting the gene expression amount of three key enzymes, H+ transport ATPase, pyruvate decarboxylase and isocitrate dehydrogenase in euglena cells by performing phenol concentration gradient domestication on the euglena cells; performing large-scale culture growth on the euglena domesticated strains, adding appropriate phenol in the culture medium, and continuously feeding the gas containing CO2; calculating the carbon fixation rate of the euglena by measuring the carbon element content in the biomass of the algal liquid during the culture process; after the culture is completed, the euglena polysaccharide content in the unit volume of the algal liquid is measured, and the phenol content in the algal liquid is measured to calculate the phenol degradation rate. The euglena cells are domesticated by using the phenol concentration gradient, the gene expression amount of the key enzymes is improved by several times, the phenol degradation capacity of the euglena cells is enhanced, the carbon fixation rate is improved, and the polysaccharide content in the cells is also improved.

This invention relates to the crystal form of vonorazine pyroglutamate and its preparation method. The vonorazine pyroglutamate crystal form obtained by this invention not only has good solubility but also excellent storage stability; in vitro activity experiments show that crystal form I of this invention is effective against H+. + K + The inhibitory effect of ATPase is comparable to that of TAK-438; animal experiments show that the crystal form of the present invention, when administered intravenously, can significantly inhibit histamine-induced gastric acid secretion in rats, and can exert its pharmacological effect faster than that of TAK-438 administered duodenally.

The invention discloses application of HSF1A in preparation of a medicine for resisting lung cancer metastasis, and relates to the technical field of anti-tumor medicines. It is found for the first time that HSF1A can be used for inhibiting non-small cell lung cancer metastasis. The HSF1A is specifically combined with a CCT1 subunit ATPase structural domain of a TRIC / CCT compound, so that the protein folding function of the TRIC / CCT compound is interfered, and three key transfer promoting signal channels including YAP, STAT3 and mTOR are inhibited at the same time. In a pulmonary metastatic tumor model constructed by mouse tail intravenous injection, the formation of pulmonary metastatic tumor is obviously reduced by the HSF1A, and the fact that the HSF1A also has strong anti-metastatic capability in an in-vivo environment is proved; the safety is high, and the development and utilization prospects are good. The invention not only provides a new application of the HSF1A, but also provides a new thought and method for adjuvant therapy of cancers.

Methods of inhibiting platelet activation and aggregation using peptide vaccines having binding specificity for the α subunit of the (Na++K+)-ATPase are provided, along with methods for inhibiting or preventing or treating thrombosis without causing bleeding.

The invention discloses a polypeptide compound and application thereof in preparation of a product for inhibiting ATP enzyme hydrolysis activity. The invention provides a polypeptide which is any one of the following: A1, the amino acid sequence of the polypeptide is sequence 1; a2, tag protein is added to the tail end of the polypeptide shown in A1, and the fused polypeptide is obtained. According to the method, multi-round progressive sequence optimization is performed by focusing a prototype peptide targeting 2C, simulating comprehensive utilization of a virtual neural network training model and actually-measured biochemical function evaluation in multiple aspects such as enzymatic inhibition and binding force evaluation, and a series of candidate peptides with relatively high comprehensive evaluation and shortened sequences are obtained; and a structural basis is provided for the design of a new round of antiviral peptidomimetic small molecules. Finally, candidate peptides are obtained through the research, and theoretical basis and technical support are provided for development of ATP enzyme inhibitors.

This invention discloses a genetically engineered bacterium for synthesizing carotenoids, its construction method, and its applications, belonging to the field of genetic engineering technology. The genetically engineered bacterium uses a carotenoid-producing yeast strain as the starting material. The gene ROX1, encoding a heme-dependent hypoxia gene repressor, is knocked out, while the expression of genes STB5 (encoding a transcription factor involved in NADPH regeneration), DID2 (encoding a class E protein in the vacuole protein sorting pathway), and VOA1 (encoding an endoplasmic reticulum protein playing a role in the assembly of the V0 region of V-ATPase) is upregulated. This invention promotes carotenoid synthesis and significantly increases carotenoid yield through combined regulation of gene expression outside the carotenoid synthesis pathway, demonstrating promising application prospects.

The application discloses a method for preparing a bacterial expression liquid by using a Malacosoma americanum V-ATPase D gene hpRNA and application thereof, and is based on a targeted Malacosoma americanum V-ATPase D gene hpRNA fragment and a virus-like particle MS2 protein gene to construct an hpV-ATPase D expression vector or an MS2+hpV-ATPase D expression vector, which is introduced into a bacterial competent cell, and MS2 protein and the targeted Malacosoma americanum V-ATPase D gene hpRNA are continuously and massively expressed by IPTG induction, so as to obtain the bacterial expression liquid, wherein the MS2 protein expressed by the MS2 protein gene is protected from being degraded by a nuclease by encapsulation, and the hpRNA of the Malacosoma americanum V-ATPase D gene has good stability; experiments show that the hpV-ATPase D and the MS2+hpV-ATPase D both have a high lethal rate on the Malacosoma americanum and have a significant inhibiting effect on development and reproduction of the Malacosoma americanum. The application uses the bacterial expression liquid containing the Malacosoma americanum V-ATPase D gene hpRNA to control the Malacosoma americanum, and has the characteristics of strong practicability, convenience, rapidness, high efficiency and sensitivity, and provides a theoretical basis for research on Malacosoma americanum control methods.

The present disclosure provides a method of treating or preventing cancer associated with elevated ASCT2 expression in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a Na + / K +-ATPase (NKA) inhibitor. Additional methods of using the Na + / K +-ATPase (NKA) inhibitors are also provided.

The invention discloses an enrichment method suitable for trace leaf plasma membrane protein, and belongs to the technical field of biology. According to the method, a mode of combining column type separation with density gradient centrifugation is adopted, components highly enriched in plasma membrane protein can be obtained through the processes of adjusting the material dosage, the centrifugation mode and the like, and the enrichment purity is improved while the separation time is saved. Compared with an untreated component, the plasma membrane labeled protein H + ATPase in the enriched component is obviously increased; meanwhile, compared with components only subjected to column type separation, chloroplast labeled protein RuBisCO ACT, cell nucleus labeled protein Histone H3 and cytoplasm labeled protein UGP are remarkably reduced. According to the method, an effective system suitable for extracting and purifying the plasma membrane protein of the catharanthus roseus leaves is established for the first time, and the method has reference significance for constructing plasma membrane protein enrichment of other plant leaves.

The invention relates to the technical field of biological medicine, and discloses a natural product for targeted inhibition of a KCNQ1 / KCNE2 complex channel and application of the natural product for targeted inhibition of the KCNQ1 / KCNE2 complex channel in preparation of a medicine for treating or preventing gastric ulcer, and an application method of a pharmaceutical composition comprises the following steps: S1, applying the pharmaceutical composition to a medication object; s2, the natural product interacts with a KCNQ1 / KCNE2 complex channel on a gastric wall cell membrane, and potassium ion current of the complex channel is inhibited; s3, weakening functions of H < + > / K < + >-ATPase in gastric wall cells by inhibiting potassium ion current, so that gastric acid secretion is reduced, and gastric ulcer is treated or prevented. According to the invention, gastric acid is indirectly regulated and controlled through targeted inhibition of gastric wall cell KCNQ1 / KCNE2 complex channels, and a new strategy for treating gastric ulcer, which is milder and has safety potential, is provided.

According to the application, an acute hypoxia animal model is established through a plateau low-pressure oxygen cabin, and the effect of cycloastragenol on prevention of acute hypoxia movement stress mice after pretreatment is evaluated. It is found that cycloastragenol after pretreatment has no adverse effect on the body, the exercise performance of mice can be improved, the exercise time can be prolonged, and gastrocnemius muscle and myocardial tissue damage can be improved. Accumulation of LAC in serum after exhaustive exercise can be remarkably reduced, accumulation of a metabolite BUN is reduced, the activity of antioxidant enzyme T-SOD in the serum is remarkably improved, and accumulation of a lipid peroxidation product MDA in the serum is reduced. The cycloastragenol can reduce the content of inflammatory factors IL-6 and TNF-alpha in serum, improve the level of Ca < 2 + >-Mg < 2 + >-ATP enzyme and Na < + >-K < + >-ATP enzyme in gastrocnemius muscle, regulate energy metabolism and improve energy supply efficiency.

Compounds and compositions for the activation of SERCA2a are disclosed. In particular, provided are compounds that act as predominantly pure or pure SERCA2a activators while only moderately inhibiting the Na+ / K+ ATPase. In general, the disclosed compounds are derivatives of androstane having the formula (I). Also disclosed herein are pharmaceutical compositions comprising one or more of the compounds of formula (I) for use for the treatment of heart failure.

Compounds and compositions for the activation of SERCA2a are disclosed. In particular, provided are compounds that act as predominantly pure or pure SERCA2a activators while only moderately inhibiting the Na+ / K+ ATPase. In general, the disclosed compounds are derivatives of androstane having the formula (I)Also disclosed herein are pharmaceutical compositions comprising one or more of the compounds of formula (I) for use for the treatment of heart failure.

Methods of preventing and treating type-1 diabetes and its complications using peptide vaccines to generate endogenous specific antibody activators that bind to the (Na++K+)-ATPase.

This invention discloses a photosynthetic nanomotor powered by a biomolecular motor and its preparation method, belonging to the field of colloidal motors. This invention aims to address the current limitations of research on the rotational dynamics of FoF1-ATP synthase molecular machines, which is limited to the motion of single and isolated objects. The photosynthetic nanomotor is prepared based on supramolecular self-assembly technology through the reconstruction of thylakoid vesicles and lecithin vesicles. The photophosphorylation system on the thylakoid membrane surface is reconstructed on the photosynthetic nanomotor. Utilizing the preserved biomolecular motor FoF1-ATPase as the power engine, under external visible light irradiation, protons generated by the photosystem accumulate in the photosynthetic liposome motor, driving the FoF1-ATPase to synthesize the energy currency ATP. Through metabolic reactions, light energy is converted into chemical energy ATP, ultimately generating self-propulsion. Due to its unique energy currency regeneration capability, the photosynthetic liposome motor has broad application prospects in the biomedical field.

The invention relates to a pharmaceutical composition, which consists of two ligand substances of Na / K-ATPase, namely an agonist substance and an antagonist substance of a receptor Na / K-ATPase / Src compound respectively. The combined use of an agonist and an antagonist can regulate the physiological functions of ion transport, in-vivo signal transduction and the like participated by Na / K-ATPase, and the safety threshold is expanded, so that the compound can be developed to diagnose or treat tumors, cardiovascular diseases and other diseases.

A method for preparing photophosphorylated nanorobots for targeted therapy of myocardial injury is disclosed. This invention aims to construct self-driven nanorobots with near-infrared light response capabilities to achieve targeted in-situ ATP supply and repair of damaged myocardium. The nanorobots of this invention are constructed based on supramolecular assembly and phospholipid phase separation principles, incorporating F-containing... o F l The pigment clusters of the ATPase and photophosphorylated protein system were co-extruded with synthetic phospholipids to form a hybrid structure with near-infrared light responsiveness. Under 850 nm near-infrared light activation, F… o F l -ATPase synergistically rotates and synchronously generates ATP, while simultaneously enhancing the directional movement capability of the nanorobots. These nanorobots can actively accumulate in areas of myocardial injury in vivo, achieving efficient lysosomal escape and deep tissue penetration, and providing in-situ ATP supply within cells to increase energy levels, restore mitochondrial function, and complete myocardial repair. This invention belongs to the field of nanorobots.

Methods of treating diseases and disorders associated with impaired lysosomal acidification, increasing lysosomal acidity, and treating diseases and disorders associated with sepsis, infection, and V-ATPase dysfunction using ZLN-005 and other compounds of formula (I), and salts, hydrates, deuterated analogs, and fluorinated analogs thereof. [Formula 1] JPEG2025537881000065.jpg3345

The present disclosure provides nucleic acid expression cassettes, vectors, compositions and methods for the treatment of ATPase-mediated diseases in a subject.

The invention relates to the field of medicines, and particularly discloses application of dapagliflozin to preparation of a medicine for preventing and / or treating obesity-related salt-sensitive hypertension. According to the application, the new application of dapagliflozin in prevention and treatment of a specific and high-risk disease subtype of obesity-related salt-sensitive hypertension is defined for the first time. Experiments prove that dapagliflozin can improve the sodium treatment function of the kidney and promote urine sodium excretion by inhibiting abnormal continuous coupling of a Na / K-ATPase / c-Src signal axis in the kidney. The discovery reveals a new kidney protection mechanism of dapagliflozin independent of the hypoglycemic effect, and provides a new drug use and a treatment scheme for clinical prevention and treatment of obesity-related renal sodium metabolism disorders and salt-sensitive hypertension.

The application discloses a method for improving the nitrification efficiency under alkaline conditions by regulating extracellular polymeric substances and ion transport. The method induces the secretion of more acidic polysaccharides and acidic organic substances in the extracellular polymeric substances of nitrifying bacteria and regulates the activities of anti-transport proteins and F0-F1 ATPase by gradually increasing the pH value of the system, the operation days and other comprehensive strategies, thereby promoting the intracellular H + input to maintain the intracellular pH stability. At the same time, the biological mineralization effect of carbonic anhydrase is utilized to accelerate the consumption of extracellular OH ‑ , improve the alkaline environmental adaptability and nitrification performance of the nitrification sludge, and significantly enrich Nitrosomonas and Nitrospira and other alkali-tolerant nitrifying bacteria, and the average ammonia nitrogen removal rate of the system under the condition of pH 10.0 can be as high as 96.6%.

A method and composition for treating viral infections using a combination of naturally occurring compounds is provided. The method includes administering to a patient at risk of or diagnosed with a viral infection a composition including therapeutically effective amounts of a helicase ATPase inhibitor, a sialidase enzyme inhibitor, an ICAM-1 inhibitor and gallic acid which each also down regulate the immune response. The composition may further include a permeation enhancer.

This invention discloses the application of P4-ATPase inhibitors in the control of plant fungal diseases and / or the regulation of plant growth. This invention discloses a novel molecular target—P4-ATPase—for the control of plant fungal diseases and / or the regulation of plant growth. Cellular and phenotypic experiments show that inhibiting this target can lead to suppression of the growth of plant pathogenic fungi and produce a growth-regulating effect on plants. This invention demonstrates that triazole compounds can directly and specifically interact physically with P4-ATPase. Triazole compounds not only bind but also effectively block the biological function of P4-ATPase. Furthermore, based on this target, other P4-ATPase inhibitors are screened for use in the control of plant fungal diseases and / or the regulation of plant growth.

The present application relates to the technical field of bioengineering, and particularly relates to a recombinant Saccharomyces cerevisiae and a construction method and application thereof, comprising the following steps: step one, using the whole genome of Enterococcus faecalis as a template, a recombinant strain SC1-1 is constructed; step two, using the recombinant strain SC1-1 as a primary strain, L-lactate dehydrogenase CYB2 gene of Saccharomyces cerevisiae is knocked out to obtain a recombinant strain SC2; step three, using the recombinant strain SC2 as a primary strain, branched-chain-2-oxo acid decarboxylase THI3 gene of Saccharomyces cerevisiae is knocked out to obtain a recombinant strain SC3; step four, using the whole genome of Saccharomyces cerevisiae as a template, a recombinant strain SC4 is constructed. The present application innovatively optimizes the source of L-lactate dehydrogenase L-LDH, knocks out L-lactate dehydrogenase CYB2 and branched-chain-2-oxo acid decarboxylase THI3, overexpresses pyruvate kinase CDC19 and H(+)-ATPase PMA2, and makes the L-lactic acid production of Saccharomyces cerevisiae increase to 33.45 g / L.

The present invention relates to a pharmaceutical composition comprising an ecto-ATPase inhibitor and a second active ingredient. It has been identified that when the ecto-ATPase inhibitor and the second active ingredient effective in treating obesity-, muscle-, or diabetes-related diseases, according to the present invention, are administered in combination, fat reduction efficacy, an increase in muscle tissue and muscle strength, and an improvement in body composition in obesity and sarcopenic obesity animal models are higher than those when each substance is administered alone. Therefore, co-administration of the ecto-ATPase inhibitor, according to the present invention, can be used as an effective treatment strategy in drug development for treating metabolic diseases such as obesity-, muscle-, or diabetes-related diseases.

The application provides application of MORC2 as a target point in preparation of a drug for treating triple negative breast cancer, and through CRISPR-Cas9 gene knockout or antisense oligonucleotide targeted silencing of MORC2, transposon element transcription can be activated, a virus simulation effect is triggered, RIG-I / MDA5-MAVS and cGAS-STING nucleic acid perception pathways are activated, interferon signals and anti-tumor immune responses are enhanced, so that the response of TNBC to ICB treatment is sensitized. Meanwhile, MORC2 interacts with the N-terminal Tudor domain of SETDB1 through its ATPase domain, cooperatively deposits H3K9me3 inhibitory modification at the TEs site; SETDB1 enhances the protein stability of MORC2 by methylating the K234 and K643 sites of MORC2, forms a positive feedback regulation loop, and targeting the regulation axis can provide a new intervention strategy for TNBC immunotherapy.

The invention relates to a lung-targeted drug-loaded micromotor as well as a preparation method and application thereof. The preparation method comprises the following steps: mixing mPEG (Polyethylene Glycol), N-t-Boc-glycine, DMAP (Dimethylaminopyridine), DCC (Dendritic Cellulose) and a solvent for reaction, and sequentially obtaining an intermediate product preparation process of mPEG-CH2CH2NH-Boc, CH3OPEG-NH2 and mPEG-NH2; performing mixed reaction on NHS, EDC and a sodium alginate solution in a buffer system to obtain a carboxyl activation process of an activated product; the mPEG-NH2 and the activated product are mixed and subjected to a reaction, and a precursor material of Alg-g-mPEG is obtained; a saturated alpha-CD aqueous solution of an FOF1-ATPase molecular motor is mixed with the Alg-g-mPEG aqueous solution, and the Alg-g-mPEG self-assembled micro-capsule with the FOF1-ATPase molecular motor coating is obtained in the carrier preparation process; mixing a drug with the self-assembled micro-capsule to obtain a lung-targeted drug-loading micro-motor; the invention further discloses application of the lung-targeted drug-loaded micromotor prepared according to the preparation method in preparation of a drug delivery system for treating lung adenocarcinoma. The double-site high-drug-loading-capacity hydrogel has the advantages of being high in double-site high drug loading capacity, high in biological safety, high in pH response self-driving capacity, good in lung tumor targeting capacity, good in lung retention capacity and the like.